Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rang in Aktien #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Aktienkurs
$150.78
Zuletzt synchronisiert: 2026-09-18
Marktkapitalisierung
$187.20B
Veränderung (1 Tag)
-0.08%
Veränderung (1 Jahr)
32.15%
Land
US
Handel Gilead Sciences, Inc. (GILD)

Kategorie

Anzahl der ausstehenden Aktien von Gilead Sciences, Inc. (GILD)
Anzahl der ausstehenden Aktien zum June 2026: 1.24B
Laut den neuesten Finanzberichten und dem Aktienkurs von Gilead Sciences, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 1.24B. Am Ende von December 2024 hatte das Unternehmen 1.25B ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Gilead Sciences, Inc. (GILD) von 2000 bis 2026
Ausstehende Aktien am Ende jedes Jahres
Jahr Ausstehende Aktien ändert
2026 (TTM) 1.24B -0.08%
2025 1.24B -0.24%
2024 1.25B -0.08%
2023 1.25B -0.56%
2022 1.26B -0.08%
2021 1.26B -0.08%
2020 1.26B -1.02%
2019 1.27B -2.16%
2018 1.30B -0.69%
2017 1.31B -2.39%
2016 1.34B -8.54%
2015 1.46B -3.81%
2014 1.52B -0.43%
2013 1.53B 0.92%
2012 1.51B -2.27%
2011 1.55B -9.48%
2010 1.71B -5.37%
2009 1.81B -1.75%
2008 1.84B -0.91%
2007 1.86B 1.19%
2006 1.84B 1.05%
2005 1.82B 5.17%
2004 1.73B 7.41%
2003 1.61B 2.84%
2002 1.56B 2.78%
2001 1.52B 4.47%
2000 1.46B 0.00%
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
Unternehmen Ausstehende Aktien Unterschied Land
892.40M -28.21%
US
2.44B 96.31%
US
1.77B 42.48%
US
796.00M -35.96%
CH
0.00 -100.00%
US